Lipanor

Ciprofibrate, the active ingredient in Lipanor, is a fibrate presented as an oral tablet for oral use. It activates peroxisome proliferator‑activated receptor alpha (PPARα) to reduce hepatic triglyceride synthesis and increase clearance of triglyceride‑rich lipoproteins, thereby lowering elevated triglyceride levels and improving overall lipid profiles in adults with hypertriglyceridaemia or mixed dyslipidaemia.

GNH USA supplies Lipanor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ciprofibrate (Lipanor) is used to manage disorders of lipid metabolism, particularly elevated triglyceride levels. - Hypertriglyceridaemia: reduces serum triglyceride concentrations. - Mixed dyslipidaemia: lowers triglycerides and modestly raises HDL‑cholesterol. - Cardiovascular risk associated with high triglycerides: contributes to overall lipid control.

Ciprofibrate may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Elevated liver enzymes: transient increases in ALT or AST. - Muscle pain: mild myalgia without weakness. - Headache: occasional tension‑type headache. - Skin reactions: rash or pruritus.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Hepatotoxicity: significant elevation of liver enzymes or jaundice. - Severe allergic reactions: anaphylaxis or angioedema. - Gallstone formation: increased risk of biliary sludge or stones. - Blood dyscrasias: leukopenia or thrombocytopenia.

When prescribing Ciprofibrate, clinicians should consider several precautionary measures to ensure safe use. - Liver function monitoring: assess baseline and periodic ALT/AST levels. - Renal function assessment: adjust use in patients with impaired clearance. - Muscle toxicity vigilance: discontinue if unexplained muscle pain or weakness occurs. - Drug‑induced gallstone risk: monitor for biliary colic symptoms. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Ciprofibrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Statins (especially high‑dose simvastatin): increased risk of rhabdomyolysis. - Gemfibrozil: additive risk of severe muscle toxicity. - Anticoagulants (warfarin): potentiation of anticoagulant effect, monitor INR. - Cyclosporine: heightened risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - Oral hypoglycemics (e.g., sulfonylureas): may enhance hypoglycaemia. - Thyroid hormones: possible alteration of thyroid hormone levels. - Bile acid sequestrants: may reduce absorption of Ciprofibrate. - NSAIDs: increased potential for renal impairment.